A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2001
11/07/2001	EP1151083A1 Nitroreductase enzymes
11/07/2001	EP1151001A2 Method for altering undesirable immune responses to polypeptides
11/07/2001	EP1151000A2 Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor
11/07/2001	EP1150994A2 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof
11/07/2001	EP1150991A2 Compositions for treating inflammatory response
11/07/2001	EP1150988A1 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
11/07/2001	EP1150965A1 Benzazepine derivatives as alpha-v integrin receptor antagonists
11/07/2001	EP1150960A1 Polymorphic crystalline forms of celecoxib
11/07/2001	EP1150959A1 Solid-state form of celecoxib having enhanced bioavailability
11/07/2001	EP1150950A2 Anthranilic acid derivatives
11/07/2001	EP1150715A1 Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
11/07/2001	EP1150714A2 Methods for inhibiting brain tumor growth
11/07/2001	EP1150708A2 Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
11/07/2001	EP1150695A2 Herbal supplement for increased muscle strength and endurance for athletes
11/07/2001	EP1150693A1 Immunogenic compositions for use as vaccines
11/07/2001	EP1150691A2 Novel antisense inhibition of rad51
11/07/2001	EP1150685A1 Phosphocholine surfactants and their use
11/07/2001	EP1150684A1 Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts
11/07/2001	EP1150678A1 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
11/07/2001	EP1150677A1 New pharmaceutical formulation
11/07/2001	EP1150674A1 Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
11/07/2001	EP1150670A2 Alkylating agents for treatment of cellular proliferation
11/07/2001	EP1150669A1 L-arginine based formulations for treating diseases and methods of using same
11/07/2001	EP1150666A1 Stimulating neutrophil function to treat inflammatory bowel disease
11/07/2001	EP1150665A2 Use of statins for treating viral infections
11/07/2001	EP1150664A2 Novel use of orexin receptor antagonists
11/07/2001	EP1150658A2 Method for controlling liposome size
11/07/2001	EP1150629A1 Drug dosage unit for buccal administration of steroidal active agents
11/07/2001	EP1150564A1 Inositol derivatives for inhibiting superoxide anion production
11/07/2001	EP1011648B1 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
11/07/2001	EP0980205A4 Method of treating malignancies
11/07/2001	EP0975380B1 Membrane system for controlled tissue regeneration in cases of diseases of the peridontium
11/07/2001	EP0845007B1 Pharmaceutical composition containing inhibitors of interferon-gamma
11/07/2001	EP0783693B1 In vitro models of cns function and dysfunction
11/07/2001	EP0777478B1 Inhibitors of rotamase enzyme activity
11/07/2001	EP0755265B1 The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure
11/07/2001	EP0600028B1 Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
11/07/2001	CN1321177A Modified starch film compositions
11/07/2001	CN1321091A Method of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
11/07/2001	CN1321089A Methods and compositions for increasing intestinal absorption of fats
11/07/2001	CN1321087A MGluR 5 antagonists for treatment of pain and anxiety
11/07/2001	CN1321086A Mucosal originated drug delivery system and animal applications
11/07/2001	CN1321080A Fast dissolving orally consumable films
11/07/2001	CN1320426A Compound for treatment of female sexual dysfuction
11/06/2001	US6313296 2-pyrrolidinone-1-acetic acid derivatives; viricides for human immunodeficiency virus (hiv); acquired immune deficiency syndrome (aids) treatment
11/06/2001	US6313168 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
11/06/2001	US6313155 Composition and method for treating macular disorders
11/06/2001	US6313144 For therapy of gastro-esophageal reflux disease, emesis, dyspepsia
11/06/2001	US6313139 Administering benzylamine derivative for therapy of psychiatric disorder in mammals
11/06/2001	US6313138 Tyrosine kinase inhibitors
11/06/2001	US6313129 Therapeutic compounds
11/06/2001	US6313112 Activating neuronal potassium adenosine triphosphate channels with diazoxide
11/06/2001	US6313098 Treating affective disorder characterized by alterations in psychometric variables as sadness, carbohydrate craving or social withdrawal by administering leptin, leptin analog, leptin fragment, leptin fusion protein or leptin
11/06/2001	US6312898 Diagnosing and treating subjects having increased risk for the development of the disease using polymerase chain reaction and/or sequencing methods to determine amino acid polymorphism in the protein
11/06/2001	US6312717 Antidepressants or anti anxiety by administering azapirone and 5-ht1a autosomal receptor antagonist
11/06/2001	US6312711 Vehicles for food and drugs, stress proteins, sequential epitopes of antigen structure
11/06/2001	US6312703 Drugs or cosmetics, liquid crystal solids and lecithin
11/06/2001	US6312694 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
11/06/2001	US6312686 Modulating the permeability of a physiological barrier with an agent that modulates tyrosine phosphorylation
11/06/2001	US6312665 Aerosol formulations for buccal and pulmonary application
11/06/2001	US6312663 Prediction of diabetes impaired wound healing by urinary nitrate assay
11/01/2001	WO2001081918A1 Transcriptionally regulated g protein-coupled receptor g2a
11/01/2001	WO2001081590A2 Protein phosphatases
11/01/2001	WO2001081585A2 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001	WO2001081577A2 Dna encoding the prost 03 polypeptide
11/01/2001	WO2001081574A2 Regulation of nf-at interacting protein nip 45 variant
11/01/2001	WO2001081573A1 Edg8 receptor, its preparation and use
11/01/2001	WO2001081562A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
11/01/2001	WO2001081540A2 Growth factor which acts through erb b-4 rtk
11/01/2001	WO2001081415A2 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/01/2001	WO2001081413A2 Isolated human transporter proteins, nucleic acids and uses thereof
11/01/2001	WO2001081412A2 Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
11/01/2001	WO2001081409A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
11/01/2001	WO2001081358A1 The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals
11/01/2001	WO2001081348A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
11/01/2001	WO2001081343A2 Compounds for treating fibromyalgia and chronic fatigue syndrome
11/01/2001	WO2001081340A2 Heterocycles that are inhibitors of impdh enzyme
11/01/2001	WO2001081325A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
11/01/2001	WO2001081312A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
11/01/2001	WO2001081310A1 1-aroyl-piperidinyl benzamidines
11/01/2001	WO2001081295A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists
11/01/2001	WO2001080896A2 Flavopiridol drug combinations and methods with reduced side effects
11/01/2001	WO2001080895A2 Methods and compositions for the treatment of cardiac indications
11/01/2001	WO2001080894A2 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
11/01/2001	WO2001080890A2 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
11/01/2001	WO2001080875A1 A memory enhancing protein
11/01/2001	WO2001080864A2 Chemical modification of mammalian urine and blood
11/01/2001	WO2001080860A2 Daily treatment for erectile dysfunction using a pde5 inhibitor
11/01/2001	WO2001080852A1 Compositions and therapies for hyperlipidaemia-associated disorders
11/01/2001	WO2001080849A1 Method of treating cancer
11/01/2001	WO2001080844A2 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
11/01/2001	WO2001080843A2 Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
11/01/2001	WO2001080832A2 Administration of a thiol-based chemoprotectant compound
11/01/2001	WO2001080829A2 Taste masking coating composition
11/01/2001	WO2001080823A2 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
11/01/2001	WO2001080713A2 Methods for non-permanent occlusion of a uterine artery
11/01/2001	WO2001080633A2 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
11/01/2001	WO2001080632A1 Cell and nonhuman animal capable of amplifying hcv
11/01/2001	WO2001056573A8 Use of cox-2 inhibitors as gastroprokinetics
11/01/2001	WO2001043754A3 Pharmaceutical composition comprised of spider venoms, the production thereof, and its use for treating tumor diseases

1 ... 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 ... 1151